Beginnings of Personalized Medicine for Myeloma

Ajai Chari, MD

Video Categories: Personalized Medicine

Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
July 25, 2018

Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer

Dr Sanjiv Agarwala describes best practices developed at St. Luke’s Cancer Center, where a committee has been formed in which clinicians and pathologists meet to reach consensus on reflex testing of molecular biomarkers, as well as the value of biomarker testing in enhancing patient care.

October 16, 2015

Pembrolizumab vs. Ipilimumab

Dr. Sanjiv Agarwala discusses the pros and cons of using Pembrolizumab over anti-CTLA4 antibody therapy.